What's breaking now, across thousands of outlets.
We haven't written up this one. The Hindu - Sci-Tech has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Sales from EU HQ'd vendor rocket in two years. The Trump affect? Yes but NIS2 and DORA are factors too
Biogen is expected to soon release the results of pivotal clinical trials of an experimental therapy for lupus.
Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.
Dr. Kalyan noted that bacteriophages selectively target disease-causing bacteria without harming human beings, making them promising alternatives when antibiotics fail
Dr. Kalyan noted that bacteriophages selectively target disease-causing bacteria without harming human beings, making them promising alternatives when antibiotics fail
Ryugu might have formed in the very first generation of planetary building blocks
